Affiliation:
1. Zealand University Hospital
Abstract
Abstract
Patients with chronic lymphocytic leukemia (CLL) are at high risk of developing severe COVID-19. The present study was undertaken to elucidate COVID-19 related morbidity and mortality in CLL patients treated with venetoclax. We present a single-center study of 108 patients with small lymphocytic lymphoma or CLL treated with venetoclax. Primary outcome was 30-day COVID-19 mortality. Secondary outcomes included COVID-19 severity and hospitalization rate. Forty-eight (44%) patients had PCR-verified SARS-COV-2 between March 2020 and January 2023. Thirty-six patients (75%) presented with asymptomatic/mild COVID-19 and 12 (25%) with severe/critical disease. The hospitalization rate was 46% with a 30-day mortality rate of only 4% and severe comorbidities as the primary cause of death. There was no significant difference in mortality when compared to venetoclax-naïve CLL patients (n = 90) from our single-center cohort with proven COVID-19. COVID-19 severity and mortality were similar before and during the Omicron era. High CIRS-scores (P < 0.02) and thrombocytopenia (P < 0.01) were more frequent in patients with severe/critical disease. In real-world data, most venetoclax treated patients presented with mild COVID-19. Hospitalization and mortality rates were low compared to data of general CLL populations. Our data indicate that venetoclax was a safe treatment option for CLL patients during the pandemic.
Publisher
Research Square Platform LLC
Reference21 articles.
1. Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL, Campus et al (2020) Leukemia 34(9): 2354–2363. https://doi.org/10.1038/s41375-020-0959-x
2. Rossi D, Shadman M, Condoluci A, Brown JR, Byrd JC, Gaidano G et al (2020) How we manage patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic Hemasphere 4(4): e432. https://doi.org/10.1097%2FHS9.0000000000000432
3. Outcomes of COVID-19 in patients with CLL: a multicenter international experience Blood;Mato AR,2020
4. Patients with CLL have a lower risk of death from COVID-19 in the Omicron era Blood;Niemann CU,2022
5. Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge;Bronstein Y;Br J Haematol,2023